跳至主要内容
临床试验/EUCTR2006-001823-20-IT
EUCTR2006-001823-20-IT进行中(未招募)不适用

A twelve-week, multicentre, double blind, randomised, parallel group, clinical study to assess the antihypertensive efficacy of delapril 15 mg b.i.d. and 30 mg b.i.d. versus lisinopril and placebo - DELPHY

CHIESI0 个研究点目标入组 616 人开始时间: 2007年3月8日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
616

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Male or female patients aged 18-75 inclusive Patients with mild to moderate hypertension defined as a mean sitting diastolic blood pressure DBP within the range of 95-109 mmHg included and mean sitting systolic blood pressure SBP inferior or equal to 179 mmHg. Patients with DBP below the above described value and whose current therapy is not providing adequate control or is producing unacceptable side effects
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Severe hypertension or secondary Orthostatic hypotension History of malignant hypertension History of miocardial infarction or coronary revascularization procedures within the last 3 months Angine pectoris requiring more than short acting nitrates, grade III and IV congestive heart failure, hemodinamically significant valvular heart disease, clinically relevant cardiac conduction abnormalities, including bradycardia, tachicardia, ventricular arrythmias History of stroke or TIA Obesity with BMI 32 Unstable diabetes with retinophaty or peripheral neuropathy and/or with insulin treatment Severe impaired liver function, renal impairment

研究者

发起方
CHIESI

相似试验

招募中
不适用
the evaluation of the efficacy and safety of Fermented garlic on improving liver functioDiseases of the digestive system
KCT0001181Bioland68
进行中(未招募)
3 期
A clinical trial, involving several sites in several countries, with a duration of 12 weeks, where patients, medical doctors and the sponsor do not know the treatment taken by the patient (between one study treatment and another one) with the scope of evaluating the safety of study treatment in comparison with another similar one in subjects with asthma.RespiratoryAsthma
ISRCTN17142179Chiesi (Italy)513
招募中
1 期
A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 pMDI 200/6/12.5 µg HFA-152a, compared to CHF5993 pMDI 200/6/12.5 µg HFA-134a, in subjects with asthmaModerate to severe controlled asthma according to Step 4 and Step 5 of the Global Initiative for Asthma (GINA) 2022 Guidelines.MedDRA version: 20.0Level: PTClassification code: 10003553Term: Asthma Class: 100000004855
CTIS2023-503333-22-00Chiesi Farmaceutici S.p.A.777
进行中(未招募)
不适用
A 12 week multi-centre, randomized, double-blind, placebo controlled evaluation of the most efficacious and tolerable dose of escitalopram in the treatment of elderly patients. - Double-blind placebo controlled study of escitalopram in the treatment of depression in the elderlyDepression in the elderly
EUCTR2005-003821-25-DKPsychiatric Hospital189
进行中(未招募)
不适用
A 12-week study in cocaine dependent subjects to evaluate safety and efficacy of a once-weekly intra-muscular injection of TV1380 (150mg/week or 300mg/per week) as a treatment to facilitate cocaine abstinence compared to placebo.Treatment for Facilitation of Abstinence in Cocaine-Dependent SubjectsMedDRA version: 16.0Level: LLTClassification code 10009815Term: Cocaine addictionSystem Organ Class: 100000004873
EUCTR2013-000208-41-ESTeva Pharmaceutical Industries Ltd.210
A twelve-week, multicentre, double blind,... | 临床试验